Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update
Solid Biosciences has secured key FDA alignment on the design of its pivotal Phase 3 IMPACT DUCHENNE trial for SGT-003, …
Friedreich’s ataxia